Actively Recruiting
PRISM-TB Study Evaluating Shortened Treatment Strategies Using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for Fluoroquinolone-Susceptible Multidrug-Resistant Tuberculosis
Led by University of California, San Francisco · Updated on 2026-09-02
400
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an international, open-label, randomized clinical trial called PRISM-TB to study treatment options for people with fluoroquinolone-susceptible multidrug-resistant or rifampin-resistant pulmonary tuberculosis FQ-S MDRRR-TB. This Phase 23 trial has two stages and aims to identify the preferred BPaLM treatment strategy with shorter or longer durations and to evaluate if this strategy is as effective as the current standard treatment at Week 73. The study uses a multi-arm, multi-stage design with a pragmatic, stratified medicine approach. Participants will be randomly assigned to one of several treatment arms. In Stage 1, they receive either the control standard of care regimen typically lasting 24 weeks with bedaquiline, pretomanid, linezolid, and moxifloxacin 6BPaLM, or one of two investigational strategies including 17 weeks of these drugs 4BPaLM or a stratified approach with 13 weeks for easier-to-treat cases and 24 weeks for harder-to-treat cases. In Stage 2, participants receive either the control regimen or the preferred treatment strategy identified from Stage 1. Drug doses and durations may be adjusted based on current international guidelines and local standards. Participants are involved for up to 73 weeks, during which their health and treatment effects are closely monitored. Researchers evaluate the primary outcome using the Desirability of Outcome Ranking DOOR at Week 73. Additional assessments include mortality and adverse events up to 28 weeks. Participants provide informed consent and must be available for home visits and phone calls. Safety is monitored throughout, and follow-up visits ensure collection of clinical data to assess treatment efficacy and tolerability over time.
CONDITIONS
Brief Title
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Research Team
G
Gustavo E Velásquez, MD, MPH
A
Ariana F Austin, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here